A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Overview

The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).

Full Title of Study: “A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 7, 2017

Detailed Description

This is a Phase 1, open-label, multicenter, two-part, dose-finding, dose-escalation study. The study is divided into two parts: Part 1 Up to five sequential dose cohorts will enroll a maximum of 6 patients each. Escalation of the pralatrexate dose, after CHOP administration (Fol-CHOP), will continue in a traditional 3+3 design, until determination of the MTD. If the MTD is not reached, the Maximum Administered Dose (MAD) of pralatrexate in combination with CHOP will be 30 mg/m2 IV on Days 1 and 8 of each 21-day cycle for up to 6 cycles. The first cohort will begin with three patients with dose A and CHOP at full dose. If none of the first three patients experiences a Dose-Limiting Toxicity (DLT), the next three patients will be enrolled in next higher dose cohort. If one of the first three patients in the first cohort experiences DLTs, an additional three patients will be enrolled into that cohort. If 2 or 3 of the first 3 patients experience DLTs, then the MTD is not found. For cohorts 2, 3, 4, and 5, If none of the first three patients experiences a DLT, the next three patients will be enrolled in next higher dose cohort. If one of the first three patients in the first cohort experiences DLTs, an additional three patients will be enrolled into that cohort. If 2 or 3 of the first 3 patients experience DLTs, then the previous cohort will be considered the MTD and up to an additional 10 patients will be enrolled at that dose in Part 2 of the study. Part 2 Once the MTD for the Fol-CHOP regimen has been established in Part 1 of the study, an additional 10 patients will be treated at the MTD (or MAD if MTD not reached) to confirm tolerability. Additionally, the PK of the established MTD of pralatrexate, when administered with CHOP at full dose, will be evaluated in these 10 patients.

Interventions

  • Drug: Pralatrexate Injection
    • Drug: Folotyn (Pralatrexate Injection) CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone

Arms, Groups and Cohorts

  • Experimental: Part 1: Dose Finding, Cohort 1
    • Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose. The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose. The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose. The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose. The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose. Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1.

Clinical Trial Outcome Measures

Primary Measures

  • Maximum Tolerated Dose
    • Time Frame: 126 Days
    • To evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL)

Secondary Measures

  • Number of participants with treatment emergent adverse events (TEAEs) using CTCAE version 4.03
    • Time Frame: 126 Days
    • Investigator will question the patient at every visit about AEs and intercurrent illnesses.
  • Objective Response Rate
    • Time Frame: 126 Days
    • To evaluate the Objective Response Rate (ORR) of 6 cycles of Fol-CHOP
  • Plasma concentration of pralatrexate in combination with CHOP
    • Time Frame: 126 Days
    • Measure the concentration of pralatrexate to evaluate the pharmacokinetics of pralatrexate when given in combination with CHOP using non-compartmental analysis.
  • Pharmacokinetics: Area Under the Curve (AUC)
    • Time Frame: 126 Days
    • Non-compartmental Analysis
  • Pharmacokinetics: Maximum Concentration (Cmax)
    • Time Frame: 126 Days
    • Non-compartmental Analysis
  • Pharmacokinetics: Time to Maximum concentration (Tmax)
    • Time Frame: 126 Days
    • Non-compartmental Analysis
  • Pharmacokinetics: Clearance (CL)
    • Time Frame: 126 Days
    • Non-compartmental Analysis

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18 years or above 2. Adequate hematologic, hepatic, and renal function 3. Histologically confirmed, new diagnosis of PTCL 4. Eligible for CHOP regimen 5. Measurable disease based on Cheson 2007 criteria 6. Eastern Cooperative Oncology Group (ECOG) performance status < 2 7. Willing to perform at least two methods of contraception 8. Negative pregnancy test of females with childbearing potential. Exclusion Criteria:

1. Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least 5 years. 2. Congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification. 3. Uncontrolled hypertension 4. Central nervous system (CNS) metastases . 5. Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment 6. Major surgery within 30 days prior to enrollment. 7. Use of any investigational drugs, biologics, or devices within 30 days prior or during the study treatment. 8. Previous exposure to pralatrexate. 9. Pregnant or breastfeeding.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Acrotech Biopharma LLC
  • Collaborator
    • Axis Clinicals Limited
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Erard Gilles, MD, Study Director, Navitas Life Sciences Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.